Further European patent was granted in May 2016 - GILUPI detection device for in vivo and/or in vitro enrichment of sample material

(PresseBox) (Potsdam, 06/30/2016)

GILUPI GmbH announced today, that the company received another European patent protecting the unique and innovative GILUPI technology.

The patent (EP2442726 B1) titles “detection device for in vivo and/or in vitro enrichment of sample material” describes a functionalized structured medical wire for the accumulation of sample material. The device comprising a biocompatible polymer and a functional surface equipped with detection receptors which for example enables the isolation of cells directly from the blood of patients (in vivo). This patented technology is already being used in clinical settings on national and international level.

The recently received patent is an important supplementation of GILUPI`s intellectual property portfolio. Thus, the company has a broad and strong intellectual property position required to run the GILUPI businesses. GILUPI has filed further patent applications that are currently subject to examination procedures for a number of inventions, hence further granted patents will follow soon.

Further European patent was granted in May 2016 - GILUPI detection device for in vivo and/or in vitro enrichment of sample material

A story by GILUPI GmbH

Published on 06/30/2016

Website Promotion

GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com

show all

Subscribe to PresseMail

Receive current and relevant stories sent to your e-mail address every day free of charge. Sign up and stay informed.

E-mail address

Daily summary: PresseBox stories including images and additional links
Always up to date: Current short news, topics and trends
Personalized information: Determine for yourself which content and keywords you are informed about and when

More information about "Medical Technology"

Category: Medical Technology

1. ePA-Summit

Mitte Januar wird sie verpflichtend eingeführt. Die Rede ist von der elektronischen Patientenakte (ePA). Auf dem ersten ePA-Summit von inno3 sollen Fragen bezüglich des operativen Einsatzes und des Rollouts geklärt werden.

read more

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.